Buy Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) Online For Sale
Genvoya is a prescription medication used to treat HIV Type 1 in adults and adolescents. It contains four medications that act in different ways to reduce viral load. The drug is taken once a day and is effective in both treatment-naive and treatment-experienced patients. However, it may induce side effects, including diarrhea, nausea, headache, decreased kidney function, and bone loss. Patients should be monitored for potential severe conditions like lactic acidosis and should discuss any concerns with their healthcare providers.
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) is a prescription medication used as a complete regimen for the treatment of human immunodeficiency virus (HIV) Type 1 in adults and adolescents. HIV is a virus that attacks the immune system, leading to acquired immunodeficiency syndrome (AIDS) if not treated appropriately.
Genvoya is a combination of four different medications, each with a unique action and function.
Elvitegravir is an integrase inhibitor that prevents the integration of the HIV viral DNA into the host cell’s DNA.
Cobicistat is a pharmacological agent that increases the bioavailability of elvitegravir. It also increases the concentration of some anti-HIV medications by inhibiting the cytochrome P450 3A enzyme.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that prevents the reverse transcription of the viral RNA into the viral DNA.
Tenofovir alafenamide is another NRTI that inhibits the reverse transcriptase enzyme, a crucial enzyme for HIV replication.
Genvoya is an oral tablet taken once daily, with or without food. It is recommended to take Genvoya at the same time every day to maintain its effectiveness. The dosage is adjusted concerning the patient’s renal function, weight, and comorbidities.
Clinical trials indicate that Genvoya is an effective medication for both treatment-naive individuals and treatment-experienced individuals who have not taken integrase inhibitors previously. In a study of treatment-naive patients, 92% had undetectable levels of HIV after 48 weeks of treatment. Similarly, in another study on treatment-experienced patients, 92% of participants with strains of the virus resistant to protease inhibitors achieved and maintained virologic suppression, as compared to 78% of patients treated with a boosted protease inhibitor.
Despite its efficacy, Genvoya may cause some side effects. The most common side effects of Genvoya include diarrhea, nausea, headache, and decreased kidney function. In some cases, patients may also experience side effects of the individual components of the drug. Additionally, Genvoya can increase the risk of bone loss, especially in women and patients with significant renal impairment, and requires adequate monitoring.
Genvoya also carries the risk of lactic acidosis, a rare but life-threatening condition that may occur due to the accumulation of acid in the blood. The risk is higher in patients with underlying health conditions, such as liver disease and pancreatitis.
In conclusion, Genvoya is a valuable treatment option for patients with HIV Type 1, providing a complete regimen for controlling the virus and reducing viral load. The medication is effective in both treatment-naive and treatment-experienced patients. Merely, it may induce side effects and potentially severe conditions, and patients should monitor their reactions to the drug closely. Additionally, patients should discuss any concerns about contraindications with other medications or treatments, and their healthcare provider will determine the best course of therapy.
30 tabs, 60 tabs, 90 tabs